keyword
MENU ▼
Read by QxMD icon Read
search

ingenol mebutate

keyword
https://www.readbyqxmd.com/read/28408848/ingenol-mebutate-in-low-amounts-for-the-treatment-of-actinic-keratosis-in-korean-patients
#1
Hyun Jae Joe, Byung Ho Oh
BACKGROUND: Ingenol mebutate (IM), a novel agent for field therapy of actinic keratosis (AK), has a drawback of inducing local skin reactions (LSRs), which may cause discomfort in patients. To reduce the LSRs, we tried the application of IM in low amounts. OBJECTIVE: The purpose of this study was to review Korean patients with AK being treated with IM and evaluate the LSRs and therapeutic outcomes of low amounts of IM. METHODS: We retrospectively reviewed 47 patients with AK on the face...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28406719/structured-expert-consensus-on-actinic-keratosis-treatment-algorithm-focusing-on-daylight-pdt
#2
Piergiacomo Calzavara-Pinton, Merete Hædersdal, Kirk Barber, Nicole Basset-Seguin, María Emilia Del Pino Flores, Peter Foley, Gaston Galimberti, Rianne Gerritsen, Yolanda Gilarbete, Sally Ibbotson, Ketty Peris, Sheetal Sapra, Eleni Sotiriou, Luis Torezan, Claas Ulrich, Jonathan Guillemot, Janek Hendrich, Rolf-Markus Szeimies
BACKGROUND: A practical and up-to-date consensus among experts is paramount to further improve patient care in actinic keratosis (AK). OBJECTIVES: To develop a structured consensus statement on the diagnosis, classification, and practical management of AK based on up-to-date information. METHODS: A systematic review of AK clinical guidelines was conducted. This informed the preparation of a 3-round Delphi procedure followed by a consensus meeting, which combined the opinions of 16 clinical experts from 13 countries, to construct a structured consensus statement and a treatment algorithm positioning daylight photodynamic therapy (dl-PDT) among other AK treatment options...
April 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28398427/disseminated-superficial-actinic-porokeratosis-treated-with-ingenol-mebutate-gel-0-05
#3
Isabella Anderson, Ethan T Routt, Shelbi C Jim On
Disseminated superficial actinic porokeratosis (DSAP) is a chronic condition characterized by numerous atrophic papules and patches with a distinctive peripheral keratotic ridge, typically found on sun-exposed areas. Treatment of DSAP is warranted not only for cosmetic and symptomatic benefits but also to prevent malignant transformation. Successful treatment of DSAP often is difficult and frequently requires the use of multiple modalities. Ingenol mebutate gel 0.05% is a topical medication primarily used for the treatment of actinic keratosis (AK) by inducing cell death...
March 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28370377/analysis-of-apoptosis-associated-molecules-erythroid-differentiation-regulator-1-bcl-2-and-p53-in-actinic-keratosis-after-treatment-with-ingenol-mebutate
#4
Yu Ri Woo, Ji Hong Lim, Seo-Won Jeong, Dae Ho Cho, Hyun Jeong Park
AK is the most common cutaneous premalignant neoplasm precursor of malignant skin tumors. The aberrant apoptotic pathway is thought to be associated with pathogenesis of AK. Ingenol mebutate has been shown to be effective and safe for treatment of AK. However, the effect of ingenol mebutate on apoptosis-related molecules using human skin samples has not been studied well. Erythroid differentiation regulator 1 (Erdr1) was recently reported to play a crucial role in malignant skin cancers like malignant melanoma...
March 31, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/28367259/united-states-food-and-drug-administration-product-label-changes
#5
Leon Kircik, Julie C Sung, Linda Stein-Gold, Gary Goldenberg
Once a drug has been approved by the United States Food and Drug Administration and is on the market, the Food and Drug Administration communicates new safety information through product label changes. Most of these label changes occur after a spontaneous report to either the drug manufacturing companies or the Food and Drug Administration MedWatch program. As a result, 400 to 500 label changes occur every year. Actinic keratosis treatments exemplify the commonality of label changes throughout the postmarket course of a drug...
February 2017: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/28300852/regression-analysis-of-local-skin-reactions-to-predict-clearance-of-actinic-keratosis-on-the-face-in-patients-treated-with-ingenol-mebutate-gel-experience-from-randomized-controlled-trials
#6
Shelbi Jim On, Kim Mark Knudsen, Torsten Skov, Mark Lebwohl
<p>Ingenol mebutate gel, a topical field treatment for actinic keratosis (AK), elicits inflammatory application-site reactions in most patients. This analysis explored the relationship between the intensity of local skin reactions (LSRs) and AK clearance, measured by the reduction in AK count from baseline in 218 patients who were treated for AK on the face in the pivotal Phase 3 studies. The analysis modeled the AK count at week 8, adjusted for baseline count, with the composite LSR score at 1 day after the last treatment application for each patient as a predictor to estimate the mean and 90% prediction interval for the percent reduction in AK count...
February 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28270072/topical-ingenol-mebutate-a-new-treatment-modality-for-multiple-actinic-keratoses-and-field-cancerization
#7
Kresimir Kostovic, Sandra Jerkovic Gulin, Zrinka Bukvic Mokos, Romana Ceovic
BACKGROUND: Ingenol mebutate gel is a recent stirring weapon recommended for the treatment of multiple actinic keratoses (AKs) and field cancerization. This review brings a summary of recent data on the treatment of AKs with ingenol mebutate (IM) providing critical commentary with regard to drug&#039;s characteristics, drug&#039;s safety profile, treatment regimen, treatment outcome, patient compliance, AK recurrence, cost-effectiveness and cost-utility, as well as guidelines for the management of the treatment of AK...
February 13, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/28263021/the-importance-of-treating-the-field-in-actinic-keratosis
#8
REVIEW
E Stockfleth
Actinic keratoses (AKs) are intraepithelial atypical proliferations of keratinocytes that develop in skin that has undergone long-term exposure to ultraviolet radiation. Given the ageing population and an increasing prevalence of AK, the socio-economic burden of AK is likely to rise over the coming years. Areas of subclinical (non-visible) sun damage in the periphery of visible AK lesions contain the same genetic changes as those found in the lesions themselves, and are known as areas of field cancerization...
March 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28224020/ingenol-mebutate-topical-gel-a-status-report-on-clinical-use-beyond-actinic-keratosis
#9
James Q Del Rosso
Ingenol mebutate is available as a topical gel formulation approved for the treatment of actinic keratosis. Two different concentrations are available for treatment of actinic keratoses at specific anatomic sites with the advantages of short durations of therapy and limited "down time" related to visible inflammation as compared to other topical agents. Due to the various modes of action of ingenol mebutate, it has also been used for treatment of disease states other than actinic keratosis. This manuscript discusses the suggested modes of action of ingenol mebutate and reviews publications on the use of ingenol mebutate gel for cutaneous disorders other than actinic keratosis, including squamous cell carcinoma in-situ, basal cell carcinoma, actinic cheilitis, anogenital warts, and others...
November 2016: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/28093603/monitoring-ingenol-mebutate-gel-treatment-of-actinic-keratoses-by-reflectance-confocal-microscopy
#10
Jose Luis López Estebaranz, Ana Pampín Franco, Reyes Gamo Villegas, Uxúa Floristán
is missing (Short communication).
January 17, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28005627/needling-assisted-drug-delivery-enhanced-response-to-ingenol-mebutate-after-microneedling
#11
Stephan A Braun, Peter A Gerber, Peter A Hevezi
No abstract text is available yet for this article.
December 21, 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28002105/variables-in-cryosurgery-technique-associated-with-clearance-of-actinic-keratosis
#12
Brian Berman, Arsalan Qazi Shabbir, Tanya MacNeil, Kim Mark Knudsen
BACKGROUND: Cryosurgery is the most commonly used method to treat actinic keratosis (AK). Cryosurgical methods are not standardized. OBJECTIVE: To examine differences in the spray techniques used for liquid nitrogen cryosurgery when treating AKs of the head, and the effect of these variations in technique on rates of complete clearance of AKs. MATERIALS AND METHODS: Patients were those from the FIELD-1 study, who received cryosurgery as per the investigators' usual practice to all AKs...
December 19, 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/27904293/superficial-basal-cell-carcinoma-treated-with-two-cycles-of-ingenol-mebutate-gel-0-015
#13
Yu Seok Jung, Ji Hae Lee, Jung Min Bae, Gyong Moon Kim
No abstract text is available yet for this article.
December 2016: Annals of Dermatology
https://www.readbyqxmd.com/read/27860083/dermoscopic-monitoring-of-efficacy-of-ingenol-mebutate-in-the-treatment-of-pigmented-and-non-pigmented-basal-cell-carcinomas
#14
Laura Diluvio, Mauro Bavetta, Monia Di Prete, Augusto Orlandi, Luca Bianchi, Elena Campione
Basal cell carcinoma is the most common non-melanoma skin cancer, and its incidence continues to raise. Although surgery can be considered the mainstay of therapy, new current pharmacological options are available and focus on tumor eradication, maximizing cosmetic results, and functional capacity. Several studies have recently reported on safety and efficacy of topical ingenol mebutate gel, a derivative of the plant Euphorbia Peplus, used to treat actinic keratosis and superficial basal cell carcinoma. In our knowledge, we report for the first time the dermoscopic evaluation of outcome and monitoring of superficial pigmented and non-pigmented basal cell carcinomas in four patients treated by this novel non-ablative agent...
January 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/27859830/fast-evaluation-and-monitoring-of-ingenol-mebutate-treatment-of-multiple-basal-cell-carcinomas-by-in-vivo-hand-held-reflectance-confocal-microscopy
#15
E Manubens, A Barreiro, A Bennassar, S Podlipnik, N Moreno, P Iglesias, J Malvehy, S Puig
Patients presenting multiple basal cell carcinomas (BCCs) are increasing and their management often entails a challenge for dermatologists(1) . In vivo reflectance confocal microscopy (RCM) has demonstrated in a recent metanalysis a very good performance in the diagnosis of BCC, opening a new alternative in the evaluation of these patients(2) . An 82 year old man with history of approximately 30 BCC over the last 30 years was referred to our clinic. This article is protected by copyright. All rights reserved...
November 11, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27853385/efficacy-of-ingenol-mebutate-gel-for-actinic-keratosis-in-patients-treated-by-thiazide-diuretics
#16
Elena Campione, Monia Di Prete, Laura Diluvio, Luca Bianchi, Augusto Orlandi
Actinic keratosis (AK) is considered as superficial squamous cell carcinoma. Chronic sun exposure plays a central role in its pathogenesis. In particular, ultraviolet B radiation causes direct damage to the DNA, producing pyrimidine dimers that suppress the protective role of p53. Other risk factors include advanced age, male sex, and fair skin type. Even some drugs used for treating blood hypertension, such as thiazide diuretics, can increase the risk of developing AK. Their photosensitizing action seems to be connected with reactive oxygen species production...
2016: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/27785771/pharmacoeconomic-considerations-in-treating-actinic-keratosis-an-update
#17
REVIEW
Spencer M Vale, Dane Hill, Steven R Feldman
Actinic keratosis is one of the most common dermatological diagnoses worldwide, especially among the elderly, fair-skinned, and immunocompromised, and is associated with a risk of transformation to skin cancer. With actinic keratosis and skin cancer prevalence increasing as the aged population expands in the US, optimizing treatment strategies may produce cost savings for the healthcare system. Since the time of our last review in 2008, investigation of the economic considerations in treating actinic keratosis has advanced...
February 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/27784514/survey-of-patient-satisfaction-with-ingenol-mebutate-gel-treatment-for-actinic-keratosis-from-a-community-dermatology-practice
#18
Dale Schaefer
Actinic keratosis (AK) is a condition that can present as a discrete lesion or as areas of confluent lesions. It is generally treated either with cryosurgery or, less frequently, with patient-applied topical medications or photodynamic therapy. Topical therapies can offer benefits over cryosurgery, especially in patients with significant actinic damage. The long durations of topical treatment required and the persistence of associated local skin reactions (LSRs) may deter some patients from adhering to topical therapies and thus affect clinical outcomes...
2016: Skinmed
https://www.readbyqxmd.com/read/27741334/biological-effects-of-ingenol-mebutate-gel-in-moderate-to-severe-actinic-fields-assessed-by-reflectance-confocal-microscopy-a-phase-i-study
#19
Martina Ulrich, Susanne Lange-Asschenfeldt, Kresten Skak, Torsten Skov, Marie Louise Østerdal, Hans-Joachim Röwert-Huber, John Robert Zibert, Eggert Stockfleth
Ingenol mebutate represents a topical treatment for fields with actinic keratosis (AK). The biological effects of ingenol mebutate in AK, subclinical (SC)-AK, and reference-skin were assessed and graded by in vivo reflectance confocal microscopy (RCM) and histology. Patients with AK and SC-AK lesions in one 25 cm2 field on hands or forearms, and with an area of reference skin on the inner upper arm, were included. The two fields were each treated with ingenol mebutate 0.05% gel (n=16), or vehicle (n=8), on 2 consecutive days; clinical and RCM assessments were performed on days 1, 2, 3, 8, and 57, and biopsies on day 3...
October 1, 2016: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/27730685/lesion-intensified-field-therapy-lift-a-new-concept-in-the-treatment-of-actinic-field-cancerization
#20
LETTER
S A Braun, P A Gerber
No abstract text is available yet for this article.
October 12, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
51369
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"